vs

Side-by-side financial comparison of MIDDLEFIELD BANC CORP (MBCN) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

MIDDLEFIELD BANC CORP is the larger business by last-quarter revenue ($19.9M vs $12.5M, roughly 1.6× Avidity Biosciences, Inc.). MIDDLEFIELD BANC CORP runs the higher net margin — 26.7% vs -1398.3%, a 1425.1% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 18.3%). MIDDLEFIELD BANC CORP produced more free cash flow last quarter ($3.4M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 13.7%).

Star Banc Corporation was a Cincinnati, Ohio-based regional bank holding company that acquired Firstar in 1998 and took the Firstar name; the merged bank acquired U.S. Bancorp in 2001 and took the U.S. Bancorp name. The company can trace its origins back to 1863 when it was first founded as the First National Bank of Cincinnati.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

MBCN vs RNA — Head-to-Head

Bigger by revenue
MBCN
MBCN
1.6× larger
MBCN
$19.9M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+415.8% gap
RNA
434.0%
18.3%
MBCN
Higher net margin
MBCN
MBCN
1425.1% more per $
MBCN
26.7%
-1398.3%
RNA
More free cash flow
MBCN
MBCN
$160.3M more FCF
MBCN
$3.4M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
13.7%
MBCN

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
MBCN
MBCN
RNA
RNA
Revenue
$19.9M
$12.5M
Net Profit
$5.3M
$-174.4M
Gross Margin
Operating Margin
32.2%
-1513.5%
Net Margin
26.7%
-1398.3%
Revenue YoY
18.3%
434.0%
Net Profit YoY
127.4%
-117.0%
EPS (diluted)
$0.65
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MBCN
MBCN
RNA
RNA
Q3 25
$19.9M
$12.5M
Q2 25
$20.5M
$3.8M
Q1 25
$18.0M
$1.6M
Q4 24
$17.5M
$3.0M
Q3 24
$16.8M
$2.3M
Q2 24
$16.8M
$2.0M
Q1 24
$16.8M
$3.5M
Q4 23
$15.4M
$2.2M
Net Profit
MBCN
MBCN
RNA
RNA
Q3 25
$5.3M
$-174.4M
Q2 25
$6.2M
$-157.3M
Q1 25
$4.8M
$-115.8M
Q4 24
$4.8M
$-102.3M
Q3 24
$2.3M
$-80.4M
Q2 24
$4.2M
$-70.8M
Q1 24
$4.2M
$-68.9M
Q4 23
$3.5M
$-60.4M
Operating Margin
MBCN
MBCN
RNA
RNA
Q3 25
32.2%
-1513.5%
Q2 25
35.9%
-4448.7%
Q1 25
31.9%
-8360.9%
Q4 24
33.4%
-4069.6%
Q3 24
16.1%
-4200.9%
Q2 24
28.8%
-4040.4%
Q1 24
29.4%
-2178.6%
Q4 23
27.7%
-3043.5%
Net Margin
MBCN
MBCN
RNA
RNA
Q3 25
26.7%
-1398.3%
Q2 25
30.0%
-4089.3%
Q1 25
26.8%
-7360.0%
Q4 24
27.8%
-3439.5%
Q3 24
13.9%
-3441.7%
Q2 24
24.7%
-3461.8%
Q1 24
24.9%
-1943.4%
Q4 23
23.0%
-2756.2%
EPS (diluted)
MBCN
MBCN
RNA
RNA
Q3 25
$0.65
$-1.27
Q2 25
$0.76
$-1.21
Q1 25
$0.60
$-0.90
Q4 24
$0.60
$-0.80
Q3 24
$0.29
$-0.65
Q2 24
$0.52
$-0.65
Q1 24
$0.51
$-0.79
Q4 23
$0.44
$-0.80

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MBCN
MBCN
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$224.1M
$1.9B
Total Assets
$2.0B
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MBCN
MBCN
RNA
RNA
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Q4 23
$185.1M
Stockholders' Equity
MBCN
MBCN
RNA
RNA
Q3 25
$224.1M
$1.9B
Q2 25
$216.1M
$1.2B
Q1 25
$213.8M
$1.3B
Q4 24
$210.6M
$1.4B
Q3 24
$210.7M
$1.5B
Q2 24
$206.8M
$1.2B
Q1 24
$205.6M
$830.9M
Q4 23
$205.7M
$500.8M
Total Assets
MBCN
MBCN
RNA
RNA
Q3 25
$2.0B
$2.1B
Q2 25
$1.9B
$1.4B
Q1 25
$1.9B
$1.5B
Q4 24
$1.9B
$1.6B
Q3 24
$1.9B
$1.6B
Q2 24
$1.8B
$1.3B
Q1 24
$1.8B
$951.5M
Q4 23
$1.8B
$628.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MBCN
MBCN
RNA
RNA
Operating Cash FlowLast quarter
$4.8M
$-156.2M
Free Cash FlowOCF − Capex
$3.4M
$-156.9M
FCF MarginFCF / Revenue
17.0%
-1257.6%
Capex IntensityCapex / Revenue
7.2%
5.7%
Cash ConversionOCF / Net Profit
0.91×
TTM Free Cash FlowTrailing 4 quarters
$32.0M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MBCN
MBCN
RNA
RNA
Q3 25
$4.8M
$-156.2M
Q2 25
$4.8M
$-199.7M
Q1 25
$8.0M
$-124.8M
Q4 24
$17.5M
$-99.9M
Q3 24
$6.0M
$-65.6M
Q2 24
$3.4M
$-65.0M
Q1 24
$5.4M
$-70.4M
Q4 23
$7.7M
$16.5M
Free Cash Flow
MBCN
MBCN
RNA
RNA
Q3 25
$3.4M
$-156.9M
Q2 25
$4.2M
$-203.0M
Q1 25
$7.7M
$-128.6M
Q4 24
$16.7M
$-103.8M
Q3 24
$5.8M
$-67.3M
Q2 24
$3.3M
$-65.5M
Q1 24
$5.3M
$-71.3M
Q4 23
$7.7M
$15.6M
FCF Margin
MBCN
MBCN
RNA
RNA
Q3 25
17.0%
-1257.6%
Q2 25
20.5%
-5277.1%
Q1 25
42.9%
-8174.3%
Q4 24
95.6%
-3491.0%
Q3 24
34.7%
-2881.8%
Q2 24
19.3%
-3204.6%
Q1 24
31.9%
-2012.3%
Q4 23
50.1%
713.1%
Capex Intensity
MBCN
MBCN
RNA
RNA
Q3 25
7.2%
5.7%
Q2 25
3.0%
86.9%
Q1 25
1.5%
238.6%
Q4 24
4.4%
131.7%
Q3 24
1.0%
72.9%
Q2 24
0.6%
26.0%
Q1 24
0.5%
25.8%
Q4 23
0.2%
39.4%
Cash Conversion
MBCN
MBCN
RNA
RNA
Q3 25
0.91×
Q2 25
0.78×
Q1 25
1.66×
Q4 24
3.60×
Q3 24
2.57×
Q2 24
0.81×
Q1 24
1.31×
Q4 23
2.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons